Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1075195 Target Snapshot

Serine/threonine-protein kinase TAO2 · SINGLE PROTEIN · Homo sapiens

759Compounds
228Assays
10Approved Drugs
360.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q9UL54. Use UniProt Q9UL54 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9UL54 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase TAO2 as ChEMBL target CHEMBL1075195, mapped to UniProt Q9UL54. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase TAO2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1075195
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9UL54
Serine/threonine-protein kinase TAO2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase TAO2 is the right protein anchor across sources, using UniProt Q9UL54 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase TAO2
UniProt AccessionQ9UL54
Component TypeProtein
Sequence Length1235 aa

Serine/threonine-protein kinase TAO2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase TAO2, mapped to UniProt Q9UL54. Sequence length is 1235 aa.

Mapped IDQ9UL54
Review nameSerine/threonine-protein kinase TAO2
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

10
Approved
5
Phase III
9
Phase II
5
Phase I
Assay Mix

Activity Type Distribution

IC5039.0
KD321.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 8.45 IC50 3.54 Preclinical
CHEMBL3688339 8.0 Kd 10.0 Preclinical
CHEMBL388978 7.92 Kd 12.0 Preclinical
CHEMBL574738 7.36 Kd 44.0 Preclinical
CHEMBL445813 7.3 Kd 50.0 Clinical
CHEMBL4063500 7.08 IC50 84.0 Preclinical
CHEMBL2334586 7.05 IC50 89.0 Preclinical
CHEMBL4554938 7.0 Kd 100.0 Preclinical
CHEMBL4554938 6.87 IC50 134.0 Preclinical
CHEMBL558752 6.85 Kd 140.0 Clinical
Distribution

pChEMBL Value Distribution

9
5.0
16
5.5
18
6.0
5
6.5
6
7.0
2
7.5
3
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
RUXOLITINIB
CHEMBL1789941
Approved 2011
CRIZOTINIB
CHEMBL601719
Approved 2011
SORAFENIB
CHEMBL1336
Approved 2005
Assay Landscape

Assay Landscape

228
Total Assays
59
Tested Compounds
1
Assay Types
Binding — 228 assays, 59 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 161 38 6.2
assay format 30 6 5.6
cell-based format 25 1 7.1
subcellular format 12 14 5.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine